Aktiesnakken — Januar 2010
-
er at EMA har godkendt... eller betinget godkendt arzerra....
-
jo sikkert munk.... det ender nok med at der bliver en lille næse til genmab... som så siger at det er gsk/ema's skyld......
-
og køberne får lov til at beholde aktierne og gevinsten... og sælgerne står med håret i postkassen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind